RBC Capital analyst Shagun Singh raised the firm’s price target on Penumbra to $222 from $205 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on PEN:

• Penumbra initiated with a Buy at Stifel

• Penumbra secures CE Mark in Europe for Lightning Flash 2.0, Lightning Bolt 7

• Inari Medical initiated with a Market Perform at Leerink

• Penumbra initiated with an Outperform at Leerink

• Penumbra price target raised to $224 from $187 at BTIG